Genetron Health’s Early Liver Cancer Screening Research Results Included in First Prevention and Treatment Guidelines for Patients in China
BEIJING--(BUSINESS WIRE)-- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its early liver cancer screening research results were cited by the "Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer" (the "Guidelines"). The Guidelines, issued by the Chinese Anti-Cancer Association, are the first national-level patient-oriented full-process guidelines for liver cancer prevention and treatment in China.
In the section on early liver cancer screening, the Guidelines emphasized that “Liquid biopsies based on circulating tumor DNA (ctDNA) have shown significant value in early screening for liver cancer. The combined detection of mutation and methylation, in combination with traditional protein biomarkers can achieve better screening results.” The liquid biopsy-based early liver cancer screening study, jointly published by Genetron Health and the National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences in the Proceedings of the National Academy of Sciences (PNAS), was cited in the Guidelines indicating a high level of awareness and regard for Genetron’s research among the expert community.
Several well-regarded oncology experts in China, including Academician Fan Jia from the Chinese Academy of Sciences, were involved in developing these Guidelines, advising patients with anti-cancer tactics spanning prevention, diagnosis, and treatment to rehabilitation.
“The scientific community considers early screening to be the most effective method for cancer prevention and control,” said Sizhen Wang, Genetron Health’s Co-founder and CEO. “Thanks to favorable government policies and the accessibility of capital, China’s cancer early screening field is seeing major technological breakthroughs. In this regard, Genetron Health has developed an innovative, world-class technology platform named the Mutation Capsule™. We are excited about the potential indicated by our first pursuit of an early screening indicator for liver cancer, and we will continue to expand to other major cancer types.”
Wang emphasized, “We will also continue to actively participate in cancer prevention and treatment projects led by the government and scientific communities. Our company intends to contribute by developing easy-to-use, accurate early screening products, in order to help accelerate China’s cancer prevention and control objectives to benefit more patients and significantly reduce family and social medical expenses.”
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding business plans, operation outlook and revenue expectation of the HCCscreen™, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Source: Genetron Holdings Limited